Background
==========

Thyroid-associated ophthalmopathy (TAO) is the commonest orbital disease in adults \[[@b1-medscimonit-25-4923]\]. Ocular lesions are caused by enlargement of the extraocular muscles and periorbital soft tissues due to activation of the surrounding connective tissues \[[@b2-medscimonit-25-4923]\]. The characteristics of TAO include upper eyelid retraction, edema, periorbital erythema, eyeball protrusion, and other manifestations. About 5%--15% of patients with TAO proceed to a more serious form of the disease although most patients have a mild or a self-limiting form \[[@b3-medscimonit-25-4923]\]. Patients with a more serious form may proceed to exposed keratitis, corneal ulcer, or optic neuropathy, thus affecting their appearance and vision and TAO can even lead to blindness \[[@b4-medscimonit-25-4923]\].

However, there are some shortcomings with the existing treatments. Glucocorticoid therapy has anti-inflammatory and immunosuppressive effects, but requires large dosages over long periods of time that might have several hormonal complications such as hyperglycemia, elevated blood pressure, and liver failure \[[@b5-medscimonit-25-4923]\]. In addition, a small number of TAO patients are not sensitive to hormonal therapy. Besides, orbital decompression surgery is invasive and needs high technical equipment with a long learning curve. Hence, it is urgent to develop new effective treatments to improve the prognosis of TAO patients.

Gypenosides, which are saponins extracted from *Gynostemma pentaphyllum*, are the most pharmacologically active components of this climbing plant and have been shown to have several bioactivities \[[@b6-medscimonit-25-4923]\]. Gypenosides can regulate the activation of immune cells and the expression of cytokines and inhibit inflammatory response in different diseases \[[@b7-medscimonit-25-4923],[@b8-medscimonit-25-4923]\]. Additionally, gypenosides can decrease the inflammatory response in inflammatory bowel disease by inhibiting the NF-κB and STAT3 signaling pathways \[[@b9-medscimonit-25-4923]\]. Moreover, gypenosides were shown to enhance Nrf2 signaling pathway and play an antioxidant role in diabetic rats \[[@b10-medscimonit-25-4923]\]. It has been reported that gypenosides not only have antiproliferation effect, but also promote apoptosis of cancer cells \[[@b11-medscimonit-25-4923],[@b12-medscimonit-25-4923]\]. Thus, gypenosides appear to have multiple potential therapeutic targets in inflammatory infiltration, fibrotic proliferation, and oxidative stress injury. TAO is an autoimmune disease in which inflammation, fibrosis, and proliferation exist throughout the disease process. In this article, we will discuss the role and mechanism of gypenosides in TAO, and explore whether gypenosides can be a new therapeutic drug for TAO.

Material and Methods
====================

Computational targets fishing
-----------------------------

The molecular formulas of gypenosides were obtained from the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (*<http://lsp.nwu.edu.cn/tcmsp.php>*) \[[@b13-medscimonit-25-4923]\] and the effective targets were predicted using Swiss Target Prediction (*<http://www.swisstargetprediction.ch/>*) \[[@b14-medscimonit-25-4923]\]. The gypenosides were collected according to the suggested screening criteria: oral bioavailability (OB) ≥30% and drug-likeness (DL) ≥0.18 \[[@b15-medscimonit-25-4923],[@b16-medscimonit-25-4923]\]. Targets of TAO were obtained from the Online Mendelian Inheritance in Man (OMIM, *<https://www.omim.org/>*) \[[@b17-medscimonit-25-4923]\], Comparative Toxicogenomic Database (CTD, *<http://ctd.mdibl.org/>*) \[[@b18-medscimonit-25-4923]\], and GeneCards Human gene database (*<https://www.genecards.org/>*) \[[@b19-medscimonit-25-4923],[@b20-medscimonit-25-4923]\]. We searched "thyroid-associated ophthalmopathy" in GeneCards and "Graves ophthalmopathy" in CTD and OMIM. The first top 500 genes of Reference Count in CTD database were collected. Common targets for gypenosides and TAO were obtained using Venny 2.1 (*<http://bioinfogp.cnb.csic.es/tools/venny/index.html>*).

Gene Ontology (GO) analysis and pathway analyses
------------------------------------------------

The Gene Ontology (GO) analysis, Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis, and Reactome Pathways analysis can provide gene expression data and systematic visual information on the hub genes. Based on common targets for this study, GO, KEGG, and Reactome Pathways analysis were performed to predict the mechanisms employed by gypenosides for treating TAO using the Database for Annotation, Visualization, and Integrated Discovery (DAVID v6.8, *<https://david.ncifcrf.gov/>*) \[[@b21-medscimonit-25-4923],[@b22-medscimonit-25-4923]\] and STRING v11.0 (*<https://string-db.org/>*).

Protein-protein interaction (PPI) network construction
------------------------------------------------------

To further understand the complex relationships among compounds, targets, and proteins, based on the information from the STRING protein query, protein-protein interaction (PPI) networks were constructed. We chose 0.70 and 0.10 as thresholds for gypenosides targets and common targets. Nodes disconnected with each other were not displayed. The visualization of the PPI networks was conducted by Cytoscape software 3.6.1.

Molecular docking
-----------------

Based on the messages of PPI networks, hub proteins were prepared for subsequent docking. The lowest energy conformations were adopted for molecular docking via default parameters using systemsDock (*<http://systemsdock.unit.oist.jp/iddp/home/index>*) \[[@b23-medscimonit-25-4923],[@b24-medscimonit-25-4923]\]. Docking score represents a negative logarithm of experimental dissociation/inhibition constant value (pKd/pKi) usually ranging from 0 to 10 (from weak to strong combining ability). The detailed information of working diagram is shown in [Figure 1](#f1-medscimonit-25-4923){ref-type="fig"}.

Results
=======

Compounds screening and targets fishing
---------------------------------------

We searched "*Gynostemmae Pentaphylli Herba*" in the TCMSP database and screened the results with the criteria OB ≥30% and DL ≥0.18. Ultimately, 9 types of gypenosides were identified and their molecular formulas were obtained ([Table 1](#t1-medscimonit-25-4923){ref-type="table"}, [Figure 2](#f2-medscimonit-25-4923){ref-type="fig"}). For each molecular formula, 15 targets were fished. Hence, 70 targets for gypenosides and 804 targets (105 from OMIM, 500 from CTD, and 237 from GeneCards, accessed November 17, 2018) for TAO were gathered after removing duplicates. We found 8 common targets between gypenosides and TAO; the common targets were PTGS2, AR, HSD11B1, NR3C1, STAT3, STAT1, STAT4, and VEGFA ([Figure 3](#f3-medscimonit-25-4923){ref-type="fig"}).

GO analysis, KEGG analysis, and Reactome Pathways analysis
----------------------------------------------------------

The top significant (cutoff criterion with statistic difference was *P*\<0.05) gene ontology categories are shown in [Figure 4](#f4-medscimonit-25-4923){ref-type="fig"}. In biological processes (BP), the common targets were mainly enriched in positive regulation of transcription from RNA polymerase II promoter (GO: 0045944); JAK-STAT cascade (GO: 0007259); positive regulation of cell migration involved in sprouting angiogenesis (GO: 0090050); transcription, DNA-templated (GO: 0006351); positive regulation of gene expression (GO: 0010628); response to drug (GO: 0042493), etc. And in molecular functions (MF), the common targets were mainly associated with RNA polymerase II core promoter proximal region sequence-specific DNA binding (GO: 0000978); transcription factor activity, sequence-specific DNA binding (GO: 0003700); DNA binding (GO: 0003677); signal transducer activity (GO: 0004871); CCR5 chemokine receptor binding (GO: 0031730); transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding (GO: 0001077); enzyme binding (GO: 0019899); steroid binding (GO: 0005496); RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding (GO: 0004879); steroid hormone receptor activity (GO: 0003707); protein homodimerization activity (GO: 0042803), and identical protein binding (GO: 0042802). In addition, cellular components (CC) analysis showed that the common targets were principally involving nuclear chromatin (GO: 0000790); cytoplasm (GO: 0005737); protein complex (GO: 0043234); nucleoplasm (GO: 0005654), and nucleus (GO: 0005634).

[Figure 5](#f5-medscimonit-25-4923){ref-type="fig"} reveals the most significant KEGG pathway of the common targets. Such common targets were enriched in pathways in cancer (hsa05200), inflammatory bowel disease (IBD) (hsa05321), pancreatic cancer (hsa05212), hepatitis B (hsa05161), JAK-STAT signaling pathway (hsa04630), microRNAs in cancer (hsa05206), VEGF signaling pathway (hsa04370), leishmaniasis (hsa05140), prolactin signaling pathway (hsa04917), chemical carcinogenesis (hsa05204), and HIF-1 signaling pathway (hsa04066). The Reactome analysis results showed common targets were enriched in interleukin-35 signaling, interleukin-21 signaling, interleukin-4 and interleukin-13 signaling, interleukin-20 family signaling, interleukin-9 signaling, and interleukin-23 signaling ([Figure 6](#f6-medscimonit-25-4923){ref-type="fig"}).

Using such a series of analyses realistically tested may provide valuable information of possible the mechanisms behind protective effects of gypenosides in TAO.

PPI network construction
------------------------

The PPI networks were obtained from the STRING database and visualized by Cytoscape 3.6.1 software. The networks of gypenosides' active compounds and associated targets showed the relationships between compounds and targets ([Figures 7](#f7-medscimonit-25-4923){ref-type="fig"}, [8](#f8-medscimonit-25-4923){ref-type="fig"}). The PPI networks showed STAT3, VEGFA, CNR1, DRD2, and DRD4 were at the center with high Degree scores. The construction of the PPI network was used to identify the hub genes of common targets ([Figure 9](#f9-medscimonit-25-4923){ref-type="fig"}). The PPI analysis indicated that STATs (STAT1, STAT3, and STAT4) were at the center of the network.

Molecular docking
-----------------

Molecular docking analysis could provide the potential binding relationships between compounds and target genes. We successfully combined STAT1 and STAT3 to gypenosides with docking scores of around 5.0 ([Figure 10](#f10-medscimonit-25-4923){ref-type="fig"}), which indicated that STAT1 and STAT3 display good binding forces with gypenosides.

Discussion
==========

In our study, GO analysis including BP, CC, and MF, was performed to annotate the hub genes \[[@b25-medscimonit-25-4923]\]. Additionally, the KEGG and Reactome pathway analyses were used to enrich the pathways of the crucial genes, which could lead to a deeper understanding of the relationships among active components, target genes, and associated pathways. The information obtained from functional and pathway enrichment analyses, PPI networks, and molecular docking analysis indicated that the common targets were significantly involved in JAK-STAT signaling pathway, pathways in cancer, and other pathways. Moreover, JAK-STAT signaling pathway showed that the STAT signaling pathway can inhibit apoptosis, and regulate cell cycle, proliferation, and differentiation ([Figure 11](#f11-medscimonit-25-4923){ref-type="fig"}). The core common targets in the JAK-STAT signaling pathway were STAT1 and STAT3. This might be evidence for gypenosides mediate proliferation and differentiation. Additionally, results of Reactome pathway enrichment indicated the common targets were mainly enriched in interleukin signaling pathways. This might indicate that gypenosides can treat TAO via anti-inflammatory action.

JAK kinase is a key family of cytoplasmic non-receptor tyrosine protein kinases and plays a pivotal role in signaling transduction pathways of many growth factors and cytokine receptors \[[@b26-medscimonit-25-4923]\]. At least 7 STAT protein family members have been identified, namely STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B, and STAT6 \[[@b27-medscimonit-25-4923]\]. Receptor-binding cytokines or growth factors can induce JAK activation and phosphorylation, thus initiating the phosphorylation of STATs \[[@b28-medscimonit-25-4923]\]. In our research, STAT1 and STAT3 are closely related to gypenosides and TAO. Research suggests that inhibiting the expression of STAT1 signaling pathway can inhibit the production of IP-10/CXCL 10 induced by IFN-γ in orbital fibroblasts of patients with TAO, thereby alleviating orbital inflammation \[[@b29-medscimonit-25-4923]\]. The STAT3 signaling pathway might play an anti-inflammatory, antioxidant, and immunomodulatory role in chronic respiratory diseases, breast cancer, and liver inflammation \[[@b30-medscimonit-25-4923]--[@b32-medscimonit-25-4923]\]. Inflammation and oxidative stress damage to orbital tissue is the main pathogenesis of TAO \[[@b33-medscimonit-25-4923],[@b34-medscimonit-25-4923]\]. Thus, STAT1 and STAT3 signaling pathway might be the crucial target signaling pathways of gypenosides in the treatment of TAO. It might reduce the tissue damage and remodeling caused by orbital inflammation and oxidative stress by regulating the expression of STAT1 and STAT3 signaling pathway.

As a traditional Chinese medicine, gypenosides have been studied in renal fibrosis, liver fibrosis, articular cartilage inflammation, oxidative stress, and apoptosis \[[@b35-medscimonit-25-4923]--[@b38-medscimonit-25-4923]\]. These studies suggest that gypenosides can play a good therapeutic role, and in cell experiments, although different cells and tissues have different sensitivity to gypenosides, high dose of gypenosides can increase apoptosis. However, there have been no reported adverse reactions to the doses used in animal experiments. Therefore, compared with the local and systemic complications caused by glucocorticoid therapy alone, the use of gypenosides might assist in the treatment of TAO and reduce the dosage of glucocorticoid and thus reduce the associated complications. And the use of gypenosides might be helpful for eye symptoms in patients with hormone-insensitive TAO. Although the existing studies are cell and experimental animal studies, and gypenosides has been used as a traditional Chinese medicine, the drug safety still needs to be verified by randomized controlled clinical trials.

Conclusions
===========

Gypenosides have been proven to have anti-inflammatory and antioxidant biological functions. Through GO analysis, PPI network construction, and molecular docking, we found that gypenosides might play an anti-inflammatory and anti-oxidative role in TAO by mediating STAT1 and STAT3 signaling pathways. Molecular docking can support the application of gypenosides in the treatment of TAO, however, the findings of these *in silico* methods need to be further verified by *in vivo* and *in vitro* experiments.
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![Venn diagram summarizing differentially targets of thyroid-associated ophthalmopathy and gypenosides.](medscimonit-25-4923-g003){#f3-medscimonit-25-4923}

![Results of Gene Ontology analysis. Cellular component results indicate the key points are nuclear chromatin and cytoplasm. Biological process results indicate that gypenosides mainly positive regulation of transcription from RNA polymerase II promoter and cell migration involved in sprouting angiogenesis. Molecular function results indicate RNA polymerase II core promoter proximal region sequence-specific DNA binding and transcription factor activity, sequence-specific DNA binding are important acting sites.](medscimonit-25-4923-g004){#f4-medscimonit-25-4923}

![Results of Kyoto Encyclopedia of Genes and Genomes pathways analysis. The results indicate that highly correlated pathways included pathways in cancer, inflammatory bowel disease (IBD), and pancreatic cancer, particularly JAK-STAT signaling pathway. RichFactor represents the ratio of target genes in the pathway and background genes of the pathway.](medscimonit-25-4923-g005){#f5-medscimonit-25-4923}

![Results of Reactome Pathways analysis. The results indicate that highly correlated pathways included interleukin-35 signaling, interleukin-21 signaling, interleukin-4 and interleukin-13 signaling and interleukin-20 family signaling.](medscimonit-25-4923-g006){#f6-medscimonit-25-4923}

![Construction of the protein-protein interaction network of gypenosides' active compounds and associated targets. Hexagons represent active compounds of gypenosides. Round rectangles represent gene symbols of targets.](medscimonit-25-4923-g007){#f7-medscimonit-25-4923}

![Construction of the protein-protein interaction network of proteins expressed by gypenosides. The 59 nodes represent 59 proteins and 148 edges represent 148 pairs of interaction among proteins. The node size and color represent Degree, while edge size and color represent combined score. The data are from STRING.](medscimonit-25-4923-g008){#f8-medscimonit-25-4923}

![Construction of the protein-protein interaction network of proteins expressed by common targets. The 8 nodes represent 8 proteins and 25 edges represent 25 pairs of interaction among proteins. The node size and color represent Degree, while edge size and color represent combined score. The data are from STRING.](medscimonit-25-4923-g009){#f9-medscimonit-25-4923}

![Heatmap shows docking scores of STATs combining to gypenosides. Docking score represents a negative logarithm of experimental dissociation/inhibition constant value (pKd/pKi).](medscimonit-25-4923-g010){#f10-medscimonit-25-4923}

![Schematic drawing to illustrate JAK-STAT signaling pathway.](medscimonit-25-4923-g011){#f11-medscimonit-25-4923}

###### 

The characteristics of the nine types of gypenosides.

  Molecule ID   Molecule name          Molecular weight   OB (%)   DL
  ------------- ---------------------- ------------------ -------- ------
  MOL009888     Gypenoside XXXVI_qt    458.80             37.85    0.78
  MOL009928     Gypenoside LXXIV       801.14             34.21    0.24
  MOL009929     Gypenoside LXXIX       785.14             37.75    0.25
  MOL009938     Gypenoside XII         785.14             36.43    0.25
  MOL009943     Gypenoside XL          799.12             30.89    0.21
  MOL009969     Gypenoside XXXV_qt     444.77             37.73    0.78
  MOL009971     Gypenoside XXVII_qt    418.73             30.21    0.74
  MOL009973     Gypenoside XXVIII_qt   416.71             32.08    0.74
  MOL009976     Gypenoside XXXII       787.11             34.24    0.25

OB -- represents oral bioavailability; DL -- represents drug-likeness.
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